Drug Trial Radar · NCT07934121
MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, phase II study designed to evaluate the efficacy and safety of mirvetuximab soravtansine combined with suvemcitug in patients with FRα-positive partially platinum-sensitive recurrent ovarian cancer. Approximately 80 patients will be enrolled. Eligible patients must have recurrent high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with FRα expression and disease recurrence occurring 6 to 12 months after completion of platinum-based chemotherapy. Participants will receive mirvetuximab soravtansine and suvemcitug every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. Tumor response will be assessed according to RECIST version 1.1. The primary objective is to evaluate the objective response rate (ORR). Secondary objectives include duration of response (DOR), progression-free survival (PFS), overall survival (OS), CA125 response, and safety outcomes. Exploratory analyses will assess the relationship between FRα expression, other biomarkers, and clinical outcomes.
Conditions
- Platinum-Sensitive Recurrent Ovarian Cancer
Interventions
Mirvetuximab SoravtansineDrug
Mirvetuximab soravtansine is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody linked to the maytansinoid DM4. It is administered intravenously in combination with suvemcitug for the treatment of patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.
SuvemcitugDrug
Suvemcitug is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). In this study, suvemcitug is administered intravenously in combination with mirvetuximab soravtansine to evaluate the efficacy and safety in patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate(ORR)Time frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.